scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
33 hedge funds and large institutions have $80M invested in scPharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
6% more funds holding
Funds holding: 31 → 33 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.07% less ownership
Funds ownership: 59.32% → 58.25% (-1.1%)
26% less capital invested
Capital invested by funds: $108M → $80M (-$27.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$765K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$175K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$96.2K |
| 4 |
TNB
Thomasville National Bank
Thomasville,
Georgia
|
+$82.5K |
| 5 |
IIA
IPG Investment Advisors
San Diego,
California
|
+$78.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
-$2.32M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$217K |
| 3 |
E
Ergoteles
New York
|
-$180K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$112K |
| 5 |
HF
HRT Financial
New York
|
-$107K |
SCPH Hedge Fund Activity: Q4 2021 in Review
33 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q4 2021, worth a combined $80M — down 26% from $108M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SCPH positions and 3 closed out — a net gain of 2 holders — while 10 added to existing stakes and 9 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $765K. The largest seller was J. Goldman & Co, cutting an estimated $2.32M.
- 33 institutional investors held scPharmaceuticals (SCPH) as of Q4 2021, up from 31 in Q3 2021.
- Funds reported $80M of scPharmaceuticals stock for Q4 2021, down 26% quarter-over-quarter.
- 5 funds opened new scPharmaceuticals positions in Q4 2021 and 3 closed out, a net change of +2 holders.
- The largest scPharmaceuticals buyer in Q4 2021 was AIGH Capital Management, an estimated $765K added.
- The largest scPharmaceuticals seller in Q4 2021 was J. Goldman & Co, an estimated $2.32M sold.
Based on aggregated 13F filings for Q4 2021.